UK CLL Forum Clinical Science Day (29th April 2008)
Jarvis Lecture Theatre, RIBA, 66 Portland Place, London
- Programme
Proliferation in CLL
Nicholas Chiorazzi
New York, USA
CLL - who are the collaborators?
Andrea Buggins
King's College, London
The aLb2 defect of CLL cells
Kathy Till
Liverpool
CD38 in CLL
Silvia Deaglio
Turin, Italy
The leukaemic microenvironment as a target for therapy in CLL
Stephen Devereux
King's College, London
Targeting NF-kB as a therapeutic strategy in CLL
Saman Hewamana
Cardiff
UK CLL Clinical Trials update
Peter Hillmen
Leeds
Local CLL Biobanking (Part 1 | Part 2)
Aneela Majid
Leicester
UK CLL Trials Biobank
Andy Pettitt
Liverpool
|
UK CLL Annual Education Day (19th Nov 2007)
- Rutherford Lecture Theatre, Institute of Physics, 76 Portland Place, London
- Programme
Overview of prognostic factors
Ulrich Jaeger, Vienna
Immunogenetic clues to the origin and behaviour of CLL
Freda Stevenson, Southampton
Chromosomal abnormalities
Thorsten Zenz, Ulm
CD38/ZAP-70 and immunophenotype
Andy Rawstron, Leeds
Serum factors
David Oscier, Bournemouth
UK CLL Clinical Trials Update
Peter Hillmen, Leeds
Prognostic factors as a guide to therapy
Peter Hillmen, Leeds
Prognostic potential of population-based studies
Martin Dyer, Leicester
Prognostic potential of gene expression profiling
Robin Foa, Rome
2007 Catovsky Prize
Fiona Bennett, Leeds
Outcome for patients with Monoclonal B-cell Lymphocytosis (MBL), a pre-cursor state for Chronic Lymphocytic Leukaemia (CLL)
Thet Thet Lin, Cardiff
CD38+ sub-populations have increased proliferative activity but similar telomere lengths and hTERT expression when compared with CD38- sub-populations derived from the same CLL patient
Aneela Majid, Leicester
BCL2 expression in chronic lymphocytic leukemia (CLL): lack of association with the BCL2 -938A>C promoter single nucleotide polymorphism (SNP)
Elaine Willmore, Newcastle
DNA-dependent protein kinase overexpression is associated with poor prognosis B CLL: a new therapeutic target
Anton Parker, Bournmouth
ZAP70 Methylation as a Prognostic Marker in CLL
|